Moreover, the mutant (mut)-p53 and associated pathway members [ADP-ribosylatin factor (ARF)-MDM2/4] are not involved in the survival of GBM patients, instead of the fact that mut-p53 has been linked to a worse cancer prognosis. Here, CDKN2A is linked to glioblastoma.